Analyst Price Target Update on BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS): The mean estimate for the short term price target for BioScrip (NASDAQ:BIOS) stands at $3.92 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $5 while the lower price target estimate is at $3.

For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Bioscrip, Inc., Golding David W, had purchased 20,000 shares in a transaction dated on August 18, 2015. The transaction was executed at $1.54 per share with total amount equaling $30,800.

BioScrip (NASDAQ:BIOS) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.55 points or 19.43% at $2.28 with 1,156,715 shares getting traded. Post opening the session at $2.5, the shares hit an intraday low of $2.27 and an intraday high of $2.6872 and the price was in this range throughout the day. The company has a market cap of $157 million and the number of outstanding shares have been calculated to be 68,780,241 shares. The 52-week high of BioScrip (NASDAQ:BIOS) is $3.93 and the 52-week low is $1.19.

BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.